CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04381663
Collaborator
(none)
60
1
36
1.7

Study Details

Study Description

Brief Summary

The study will consist of two parts:
  • In Study A, objectively assessed physical activity, gait, balance, range of movement of specific joints during walking and neurophysiological findings between patients with cervical spine stenosis (CSS) without myelopathy who will be treated conservatively and patients with stenosis and signs of myelopathy who are candidates for surgical Treatment will be compared.

  • In Study B, the 6-month changes in the same outcomes in patients treated conservatively (from the first specialist consultation until 6 months later) and in patients treated surgically (preoperative day and 6-month post-operatively) will be quantified.

Condition or Disease Intervention/Treatment Phase
  • Procedure: conservative treatment
  • Procedure: surgical treatment

Detailed Description

Study A is a single centre cross-sectional study with two study groups, one that will be treated conservatively (stenosis) and one that will be treated surgically (stenosis and myelopathy).

Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment.

Clinical, radiological, biomechanical (kinematic and electromyographic), neurological and neurophysiological data will be collected. Differences in and the relationship between the clinical, radiological, biomechanical, neurological and neurophysiological data will be determined .

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes
Actual Study Start Date :
Sep 16, 2019
Anticipated Primary Completion Date :
Mar 15, 2022
Anticipated Study Completion Date :
Sep 15, 2022

Arms and Interventions

Arm Intervention/Treatment
conservative treatment

In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment

Procedure: conservative treatment
conservative treatment for patients with cervical spine stenosis without myelopathy

surgical treatment (stenosis and myelopathy).

In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment

Procedure: surgical treatment
surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy

Outcome Measures

Primary Outcome Measures

  1. Difference in gait symmetry [approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2]

    The subjects will perform an instrumented gait analysis on an overground walkway with two embedded force plates

  2. Change in balance performance [approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    Balance performance will be assessed using the modified clinical test of sensory integration of balance (m-CTSIB) using the Biodex Balance System SD

  3. Difference in neurophysiological outcome [approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    Quantitative score of Motor evoked potentials (MEP) and Somato-sensory evoked potentials (SEP)

Secondary Outcome Measures

  1. Difference in daily physical activity [monitored for 7 consecutive days at visit 1 or 1 week before surgery and 6 months later at visit 2]

    daily physical activity will be objectively monitored for 7 consecutive days using the ActiGraph wGT3X-BT (ActiGraph Corp, Pensacola Florida, USA) worn around the hip

  2. Difference in spinal cord gray and white matter areas [approximate duration of the scan: 30. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2 (Measurement at visit 2 only in patients with cervical spine stenosis treated conservatively).]

    Participants will be investigated on the 3 Tesla (3T) whole body MRI research scanner using 2D-Averaged Magnetization Inversion Recovery Acquisitions (AMIRA) imaging

  3. Change in segmental quantitative muscle strength [approximate duration: 10 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    assessments of segmental muscle force via hand-held-dynamometry following the Treatment Research Initiative to Cure ALS (TRICALS) Protocol Isometric Strength Testing 2016 at each study visit

  4. Change in 25-foot walk test [approximate duration: 3 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    time of 25-foot walk test

  5. Change in 6-minute walk test [approximate duration: 6 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    distance of 6-minute walk test

  6. Change in dynamic stability and range of motion during walking [approximate duration: 20 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    Subjects will first complete overground walking trials in their own shoes at normal and fast walking speed while naming months backward in a 25-m hallway while gait CSS Study Protocol Version 2, 15.8.2019 Page 12 of 21 kinematics will be recorded using the RehaGait system. Afterwards, patients will be asked to walk over the force plates in the laboratory at their preferred walking speed while kinematic, kinetic and Electromyography (EMG) data will be recorded.

  7. Change in pain [approximate duration: 2 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    Numeric Pain Rate Scale (NPRS), a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain)

  8. Change in function [approximate duration: 13 min. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2]

    Modified Japanese Orthopaedic Association - Scoring System (mJOA) questionnaire, This scale consists of four domain scores motor dysfunction in the upper extremities, motor dysfunction in the lower extremities, sensory function in the upper extremities and bladder function. Each scale ranges from 0 to 7, 5, 3, and 3, respectively, with a total score of 0 to 18. The severity of myelopathy is defined as mild if the mJOA score is 15 or larger, moderate if the mJOA score ranges from 12 to 14 or severe if the mJOA score is less than 12

  9. Change in disability [approximate duration: 5 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    Neck Disability Index (NDI) questionnaire, a Patient-completed, condition-specific functional status questionnaire with 10 items including pain, personal care, lifting, reading, headaches, concentration, work, driving, sleeping and recreation. The NDI has sufficient support and usefulness to retain its current status as the most commonly used self-report measure for neck pain. A score of 0-4 points means no disability, 5-14 points mild disability, 15-24 points moderate disability, 25-34 points severe disability, 35-50 points complete disability

  10. Change in risk of falling [approximate duration: 10 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2.]

    The Berg Balance Scale (BBS) is a subjective measure for balance and risk of falling. Based on 14 items, vestibular function, balance ability, proprioception and muscle strength are assessed. The cut-off value for an elevated risk of falling is at 38 of 56 points. Older persons with a score of 45 of 56 points are able to ambulate safely and independently.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age > 18 years

  • Diagnosis of degenerative cervical spine stenosis defined by MRI (stenosis grade 2 or grade 3

  • Local clinical symptoms due to degenerative changes of the cervical vertebral column with or without clinically defined myelopathy

Exclusion Criteria:
  • Stenosis after trauma or neoplasm

  • Prior decompressive surgery

  • Previous spine or extremity surgery with a consequent sensorimotor impairment

  • Other pathologies than cervical spine stenosis causing gait disturbance

  • BMI > 35 kg/m2

  • Use of walking aids

  • Inability to provide informed consent

  • Contraindications for recording of Motor evoked potentials (MEP)

  • Contraindications to safely undergo MRI

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitätsspital Basel Basel Switzerland 4031

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Annegret Mündermann, Prof. Dr., University Hospital, Basel, Switzerland
  • Principal Investigator: Cordula Netzer, Dr. med., University Hospital, Basel, Switzerland
  • Principal Investigator: Regina Schläger, PD Dr. med., University Hospital, Basel, Switzerland
  • Principal Investigator: Martin Hardmeier, PD Dr. med., University Hospital, Basel, Switzerland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT04381663
Other Study ID Numbers:
  • 2019-01270;ch20Muendermann
First Posted:
May 11, 2020
Last Update Posted:
Jun 29, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Basel, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2021